Summit’s ivonescimab cuts death risk by 27% versus Keytruda in lung cancer trial
nopparit/iStock via Getty Images
Summit Therapeutics (SMMT) on Sunday said ivonescimab significantly extended survival compared with Merck’s (MRK) Keytruda in a late-stage lung cancer trial conducted by its partner Akeso (AKESF) in China.
Ivonescimab reduced the risk of death by 27% compared with Keytruda, also known
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.